## **CLAIMS**

1) Amino acid diamides in non  $\alpha$  position of formula (1)

$$R_1$$
 $R_2$ 
 $R_2$ 
 $R_1$ 
 $R_2$ 
 $R_2$ 
 $R_1$ 

n = 2 to 8

10

5

(1)

wherein R<sub>1</sub> is selected from amongst the group consisting of functional groups halogen, NO<sub>2</sub>, OH, OCH<sub>3</sub> either alone or associated and R<sub>2</sub> is selected from the group consisting of functional groups H, alkyl, halogen, NO<sub>2</sub>, OH, OCH<sub>3</sub>, which are useful as adjuvants for the administration of biological active agents.

2) Compounds according to claim 1, characterised in that they they present the following structure:

20

15

$$n = 2 \text{ to } 8$$

25

(2)

3) Compounds according to claim 1, characterised in that they they present the following structure:

5

10

15

35

4) Compounds according to claim 1, characterised in that they present the following structure:

O<sub>2</sub>N COOH
$$n = 2 \text{ to } 8$$
(4)

- 20 5) Pharmaceutical compositions according to claims 1 to 4, characterised in that they comprise heparin oligosaccharides and at least one compound from formula (1)
- 6) Pharmaceutical compositions according to claim 5, characterised in that they comprise compounds according to formula (2) and glycosaminoglycan oligosaccharides.
- 7) Pharmaceutical compositions according to claim 5, characterised in that they comprise compounds according to formula (3) and glycosaminoglycan oligosaccharides.
  - Pharmaceutical compositions according to claim 5, characterised in that they comprise compounds according to formula (4) and glycosaminoglycan oligosaccharides.
  - 9) Pharmaceutical compositions according to claims 5 and 6, characterised in that they comprise at least one compound of structure

- 5 and Bemiparin.
  - 10) Pharmaceutical compositions according to claims 5 and 7, characterised in that they comprise at least one compound of structure

and Bemiparin.

15 11) Pharmaceutical compositions according to claims 5 and 8, characterised in that they comprise at least one compound of structure

and Bemiparin.

- 12) Pharmaceutical compositions according to any of the preceding claims, characterised in that they comprise compounds according to formula (1) and at least one active agent selected from the group composed of heparin, dermatan sulphate, condroitin sulphate, heparan sulphate and oligosaccharide derivatives.
- 13) Use of a compound according to any of the claims 1 to 4 for the manufacture of an antithrombotic medication.

10

20

25

14) Use of a compound according to any of the claims 1 to 4 for the manufacture of a medication for the treatment of a disease selected from the group composed of inflammation, cancer and allergy.